ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · see citing works

Features and development of Coot

Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. D. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 27,510 · see citing works

<i>PHENIX</i> : a comprehensive Python-based system for macromolecular structure solution

Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716 · see citing works

<i>Phaser</i> crystallographic software

McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612 · see citing works

SWISS-MODEL: homology modelling of protein structures and complexes

Waterhouse, A. M., Bertoni, M., Bienert, S., Studer, G., Tauriello, G., Gumienny, R., Heer, F. T., de Beer, T., Rempfer, C., Bordoli, L., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky427 · Cited by 13,005 · see citing works

Mutations of the BRAF gene in human cancer

Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · see citing works

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · see citing works

PHENIX: a comprehensive Python-based system for macromolecular structure solution

Adams, P. D., Afonine, P. V., Bunkòczi, G., Chen, V. B., Davis, I., Echols, N., Headd, J. J., Hung, L., Kapral, G. J., Grosse‐Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334 · see citing works

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496 · see citing works

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770 · see citing works

Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay

Molina, D. M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., & Nordlund, P. (2013) · Science · doi:10.1126/science.1233606 · Cited by 2,261 · see citing works

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051 · see citing works

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

Poulikakos, P. I., Zhang, C., Bollag, G. E., Shokat, K. M., & Rosen, N. X. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,818 · see citing works

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

Hatzivassiliou, G., Song, K. W., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G. P. A., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,614 · see citing works

<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib

Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598 · see citing works

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

Heidorn, S. J., Milagre, C. S., Whittaker, S. R., Nourry, A., Niculescu‐Duvaz, I., Dhomen, N. S., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C. A., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,468 · see citing works

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460 · see citing works

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454 · see citing works

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Long, G. V., Stroyakovskiy, D., Gogas, H. J., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60898-4 · Cited by 1,397 · see citing works

BRAF mutation predicts sensitivity to MEK inhibition

Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G. A., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2005) · Nature · doi:10.1038/nature04304 · Cited by 1,329 · see citing works

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

Villanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga‐Kalabis, M., Cipolla, A. K., Wubbenhorst, B. S., Xu, X., Gimotty, P. A., Kee, D., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.023 · Cited by 1,261 · see citing works

RAS-targeted therapies: is the undruggable drugged?

Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103 · see citing works

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

Dummer, R., Ascierto, P. A., Gogas, H. J., Arance, A. M., Mandalà, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsová, I., Gutzmer, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30142-6 · Cited by 1,034 · see citing works

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

Ascierto, P. A., McArthur, G. A., Dréno, B., Atkinson, V. G., Liszkay, G., Giacomo, A. M. D., Mandalà, M., Демидов, Л. В., Stroyakovskiy, D., Thomas, L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30122-x · Cited by 1,023 · see citing works

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of <i>BRAF</i> -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

Corcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022 · see citing works

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

Hata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4040 · Cited by 985 · see citing works

Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations

Bueno, R., Stawiski, E. W., Goldstein, L. D., Durinck, S., Rienzo, A. D., Modrusan, Z. D., Gnad, F., Nguyen, T. T., Jaiswal, B. S., Chirieac, L. R., et al. (2016) · Nature Genetics · doi:10.1038/ng.3520 · Cited by 920 · see citing works

The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma

Allen, E. M. V., Wagle, N., Sucker, A., Treacy, D. J., Johannessen, C. M., Goetz, E. M., Place, C. S., Taylor-Weiner, A. N., Whittaker, S. R., Kryukov, G. V., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0617 · Cited by 904 · see citing works

An Optimized microRNA Backbone for Effective Single-Copy RNAi

Fellmann, C., Hoffmann, T., Sridhar, V., Hopfgartner, B., Muhar, M., Roth, M., Lai, D. Y., Barbosa, I. A. M., Kwon, J. S., Guan, Y., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.11.020 · Cited by 705 · see citing works

The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo

Meerbrey, K. L., Hu, G., Kessler, J. D., Roarty, K. P., Li, M. Z., Fang, J. E., Herschkowitz, J. I., Burrows, A. E., Ciccia, A., Sun, T., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019736108 · Cited by 667 · see citing works

Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras

Wang, T., Yu, H., Hughes, N. W., Liu, B., Kendirli, A., Klein, K., Chen, W. W., Lander, E. S., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.01.013 · Cited by 632 · see citing works

Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma

Montagut, C. O., Sharma, S. V., Shioda, T., McDermott, U., Ulman, M. J., Ulkus, L. E., Dias-Santagata, D. C., Stubbs, H., Lee, D. W., Singh, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6787 · Cited by 508 · see citing works

Studying clonal dynamics in response to cancer therapy using high-complexity barcoding

Bhang, H.-E. C., Ruddy, D. A., Krishnamurthy Radhakrishna, V., Caushi, J. X., Zhao, R., Hims, M. M., Singh, A. P., Kao, I., Rakiec, D., Shaw, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3841 · Cited by 507 · see citing works

Differential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases

Marais, R., Light, Y., Paterson, H. F., Mason, C., & Marshall, C. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4378 · Cited by 455 · see citing works

Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?

Zhao, Z., Wu, H., Wang, L., Liu, Y., Knapp, S., Liu, Q., & Gray, N. S. (2014) · ACS Chemical Biology · doi:10.1021/cb500129t · Cited by 450 · see citing works

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Hanna, N. H. (2008) · Yearbook of Oncology · doi:10.1016/s1040-1741(08)79219-4 · Cited by 386 · see citing works

c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma

Blasco, R. B., Francoz, S., Santamaría, D., Cañamero, M., Dubus, P., Charron, J., Baccarini, M., & Barbacid, M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.002 · Cited by 302 · see citing works

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

Peng, S.-B., Henry, J. R., Kaufman, M. D., Lu, W.-P., Smith, B. D., Vogeti, S., Rutkoski, T. J., Wise, S., Chun, L., Zhang, Y., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.002 · Cited by 298 · see citing works

Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas

Fransén, K. (2003) · Carcinogenesis · doi:10.1093/carcin/bgh049 · Cited by 268 · see citing works

Structure of the BRAF-MEK Complex Reveals a Kinase Activity Independent Role for BRAF in MAPK Signaling

Haling, J. R., Sudhamsu, J., Yen, I., Sideris, S., Sandoval, W. N., Phung, W., Bravo, B. J., Giannetti, A. M., Peck, A., Masselot, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.007 · Cited by 253 · see citing works

Mutant BRAF Melanomas—Dependence and Resistance

Poulikakos, P. I., & Rosen, N. X. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.008 · Cited by 250 · see citing works

Mutations of C-RAF Are Rare in Human Cancer because C-RAF Has a Low Basal Kinase Activity Compared with B-RAF

Emuss, V., Garnett, M. J., Mason, C., The Cancer Genome Project, & Marais, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1683 · Cited by 209 · see citing works

Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA

Clark, T. A., Chung, J. H., Kennedy, M., Hughes, J. D., Chennagiri, N., Lieber, D. S., Fendler, B., Young, L., Zhao, M., Coyne, M., et al. (2018) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.05.004 · Cited by 200 · see citing works

Ins and Outs of Kinase DFG Motifs

Treiber, D. K., & Shah, N. P. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.06.001 · Cited by 174 · see citing works

Somatic activating ARAF mutations in Langerhans cell histiocytosis

Nelson, D. S., Quispel, W. T., Badalian‐Very, G., van Halteren, A. G. S., van den Bos, C., Bovée, J. V. M. G., Tian, S. Y., Hummelen, P. V., Ducar, M. A., MacConaill, L. E., et al. (2014) · Blood · doi:10.1182/blood-2013-06-511139 · Cited by 173 · see citing works

Malignant Melanoma in the 21st Century: The Emerging Molecular Landscape

Sekulić, A., Haluska, P., Miller, A. J., Lamo, J. G. D., Ejadi, S., Pulido, J. S., Salomão, D. R., Thorland, E. C., Vile, R. G., Swanson, D. C., et al. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.7.825 · Cited by 142 · see citing works

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Bean, J. M., Brennan, C. W., Shih, J.-Y., Riely, G. J., Viale, A. J., Wang, L., Chitale, D. A., Motoi, N., Szőke, J., Broderick, S., et al. (2007) · Molecular Cancer Therapeutics · Cited by 123 · see citing works

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors

Desai, J., Gan, H. K., Barrow, C., Jameson, M. B., Atkinson, V. G., Haydon, A. M., Millward, M., Begbie, S. D., Brown, M. P., Markman, B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02654 · Cited by 116 · see citing works

A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas

Sun, Y., Alberta, J. A., Pilarz, C., Calligaris, D., Chadwick, E. J., Ramkissoon, S. H., Ramkissoon, L. A., Matía, V., Mazzola, E., Goumnerova, L. C., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now261 · Cited by 107 · see citing works

Negative regulation of RAF kinase activity by ATP is overcome by 14-3-3-induced dimerization

Liau, N. P. D., Wendorff, T. J., Quinn, J. G., Steffek, M., Phung, W., Liu, P., Tang, J., Irudayanathan, F. J., Izadi, S., Shaw, A. S., et al. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0365-0 · Cited by 96 · see citing works

Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition

Yaeger, R., Yao, Z., Hyman, D. M., Hechtman, J. F., Vakiani, E., Zhao, H., Su, W., Wang, L., Joelson, A., Cercek, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0768 · Cited by 94 · see citing works

LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors

Monaco, K., Delach, S. M., Yuan, J., Mishina, Y. M., Fordjour, P., Labrot, E., McKay, D., Guo, R., Higgins, S., Wang, H. Q., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2563 · Cited by 88 · see citing works

ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers

Rebocho, A. P., & Marais, R. (2012) · Oncogene · doi:10.1038/onc.2012.330 · Cited by 83 · see citing works

BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF -Mutated Colorectal Cancers

Tang, Z., Yuan, X., Du, R., Cheung, S.-H., Zhang, G., Wei, J., Zhao, Y., Feng, Y., Peng, H., Zhang, Y., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0262 · Cited by 79 · see citing works

C-Raf Inhibits MAPK Activation and Transformation by B-RafV600E

Karreth, F. A., DeNicola, G. M., Winter, S. P., & Tuveson, D. A. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.10.017 · Cited by 64 · see citing works

RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma

Dorard, C., Estrada, C., Barbotin, C., Larcher, M., Garancher, A., Leloup, J., Beermann, F., Baccarini, M., Pouponnot, C., Larue, L., et al. (2017) · Nature Communications · doi:10.1038/ncomms15262 · Cited by 55 · see citing works

Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study.

Kim, T. W., Lee, J., Shin, S. J., Kim, J.-S., Kim, Y. J., Han, H. S., Lee, S. J., Lim, H., Hong, Y.-H., Noh, Y. S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.3000 · Cited by 49 · see citing works

Mutational analysis of the ARAF gene in human cancers

Lee, J. W., Soung, Y. H., Kim, S. Y., Park, W. S., Nam, S. W., Min, W. S., Kim, S. H., Lee, J. Y., Yoo, N. J., & Lee, S. H. (2005) · Apmis · doi:10.1111/j.1600-0463.2005.apm1130108.x · Cited by 47 · see citing works

Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic

Ramurthy, S., Taft, B. R., Aversa, R. J., Barsanti, P. A., Burger, M. T., Lou, Y. C., Nishiguchi, G., Rico, A. C., Setti, L., Smith, A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00161 · Cited by 44 · see citing works

RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors

Yuan, X., Tang, Z., Du, R., Yao, Z., Cheung, S., Zhang, X., Wei, J., Zhao, Y., Du, Y., Liu, Y., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12698 · Cited by 40 · see citing works

CSIG-19. FHL2 INTERACTS WITH EGFRVIII TO PROMOTE GLIOBLASTOMA GROWTH

Sun, L., Lan, Q., & Li, M. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox168.213 · Cited by 7 · see citing works

Signal pathways of melanoma and targeted therapy

Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 403 · see citing works

Small molecule inhibitors targeting the cancers

Liu, G., Chen, T., Zhang, X., Ma, X., & Shi, H. (2022) · MedComm · doi:10.1002/mco2.181 · Cited by 198 · see citing works

E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers

Park, H., & Baek, K. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188736 · Cited by 180 · see citing works

The RASopathies: from pathogenetics to therapeutics

Hebron, K. E., Hernandez, E. R., & Yohe, M. E. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049107 · Cited by 167 · see citing works

Molecular Pathways and Mechanisms of BRAF in Cancer Therapy

Poulikakos, P. I., Sullivan, R. J., & Yaeger, R. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2138 · Cited by 145 · see citing works

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

Weiss, A., Lorthiois, E., Barys, L., Beyer, K. S., Bomio-Confaglia, C., Burks, H., Chen, X., Cui, X., de Kanter, R., Dharmarajan, L., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0158 · Cited by 150 · see citing works

BRAF — a tumour-agnostic drug target with lineage-specific dependencies

Hanrahan, A. J., Chen, Z., Rosen, N., & Solit, D. B. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00852-0 · Cited by 136 · see citing works

RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms

Yang, X., & Wu, H. K. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01631-9 · Cited by 123 · see citing works

Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS

Yin, G., Huang, J., Petela, J., Jiang, H., Zhang, Y., Gong, S., Wu, J., Liu, B., Shi, J., & Gao, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01441-4 · Cited by 87 · see citing works

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

Tang, D., Kroemer, G., & Kang, R. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01422-7 · Cited by 80 · see citing works

Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib

Tkacik, E., Li, K., Pino, G. L. G., Ha, B. H., Viñals, J., Park, E., Beyett, T. S., & Eck, M. J. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104634 · Cited by 75 · see citing works

Structural basis for SHOC2 modulation of RAS signalling

Liau, N. P. D., Johnson, M. C., Izadi, S., Gerosa, L., Hammel, M., Bruning, J. M., Wendorff, T. J., Phung, W., Hymowitz, S. G., & Sudhamsu, J. (2022) · Nature · doi:10.1038/s41586-022-04838-3 · Cited by 56 · see citing works

The evolution of BRAF-targeted therapies in melanoma: overcoming hurdles and unleashing novel strategies

İmani, S., Roozitalab, G., Emadi, M., Moradi, A., Behzadi, P., & Kaboli, P. J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1504142 · Cited by 62 · see citing works

The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers

Ryan, M. B., Quade, B., Schenk, N., Fang, Z., Zingg, M., Cohen, S. E., Swalm, B. M., Li, C., Özen, A., Ye, C., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0139 · Cited by 51 · see citing works

Transformer-Based Generative Model Accelerating the Development of Novel BRAF Inhibitors

Yang, L., Yang, G., Bing, Z., Tian, Y., Niu, Y., Yang, L., & Yang, L. (2021) · ACS Omega · doi:10.1021/acsomega.1c05145 · Cited by 51 · see citing works

Harness the functions of gut microbiome in tumorigenesis for cancer treatment

Lee, M. (2021) · Cancer Communications · doi:10.1002/cac2.12200 · Cited by 50 · see citing works

Mechanistic model of MAPK signaling reveals how allostery and rewiring contribute to drug resistance

Fröhlich, F., Gerosa, L., Muhlich, J. L., & Sorger, P. K. (2023) · Molecular Systems Biology · doi:10.15252/msb.202210988 · Cited by 48 · see citing works

CRAF dimerization with ARAF regulates KRAS-driven tumor growth

Venkatanarayan, A., Liang, J., Yen, I., Shanahan, F., Haley, B., Phu, L., Verschueren, E., Hinkle, T. B., Kan, D., Segal, E., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110351 · Cited by 45 · see citing works

New Approaches to Targeted Therapy in Melanoma

Fernandez, M. F., Choi, J. S., & Sosman, J. A. (2023) · Cancers · doi:10.3390/cancers15123224 · Cited by 44 · see citing works

Targeting CRAF kinase in anti-cancer therapy: progress and opportunities

Wang, P., Laster, K. V., Jia, X., Dong, Z., & Liu, K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01903-x · Cited by 40 · see citing works

The role of CRAF in cancer progression: from molecular mechanisms to precision therapies

Riaud, M., Maxwell, J., Soria‐Bretones, I., Dankner, M., Li, M., & Rose, A. A. N. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-023-00650-x · Cited by 39 · see citing works

New prospectives on treatment opportunities in RASopathies

Gelb, B. D., Yohe, M. E., Wolf, C. M., & Andelfinger, G. (2022) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.32024 · Cited by 39 · see citing works

Drug resistance in targeted cancer therapies with RAF inhibitors

Degirmenci, U., Yap, J., Sim, Y. R. M., Qin, S., & Hu, J. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.36 · Cited by 36 · see citing works

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope

Yang, H. S., Zhou, X., Fu, D., Le, C., Wang, J., Zhou, Q., Liu, X., Yuan, Y., Ding, K., & Xiao, Q. (2022) · 癌症：英文版 · doi:10.1002/cac2.12377 · Cited by 35 · see citing works

Circulating Tumour DNA in Melanoma—Clinic Ready?

Tivey, A., Britton, F., Scott, J.-A., Rothwell, D. G., Lorigan, P. C., & Lee, R. J. (2022) · Current Oncology Reports · doi:10.1007/s11912-021-01151-6 · Cited by 33 · see citing works

The future of targeted kinase inhibitors in melanoma

Caksa, S., Baqai, U., & Aplin, A. E. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108200 · Cited by 33 · see citing works

Cooperation between the Hippo and MAPK pathway activation drives acquired resistance to TEAD inhibition

Paul, S., Hagenbeek, T. J., Tremblay, J., Kameswaran, V., Ong, C. C., Liu, C., Guarnaccia, A. D., Mondo, J. A., Hsu, P., Kljavin, N. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56634-y · Cited by 31 · see citing works

A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF -Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation

Yaeger, R. D., McKean, M. A., Haq, R., Beck, J. T., Taylor, M. H., Cohen, J. E., Bowles, D. W., Gadgeel, S. M., Mihalcioiu, C. L. D., Papadopoulos, K. P., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0024 · Cited by 28 · see citing works

Disrupted molecular glue complex drives RAS inhibitor resistance

Sang, B., Ye, L. F., Fu, Z., Pourfarjam, Y., Cuevas-Navarro, A., Fan, S., Hu, F., Washington, A., Rodriguez, D. J., Vides, A., et al. (2026) · Cell · doi:10.1016/j.cell.2026.03.031 · Cited by 42 · see citing works

Targeting the SHOC2–RAS interaction in RAS-mutant cancers

Hauseman, Z. J., Stauffer, F., Beyer, K. S., Mollé, S., Cavicchioli, E., Marchand, J., Fodor, M., Viscomi, J. S., Dhembi, A., Katz, S., et al. (2025) · Nature · doi:10.1038/s41586-025-08931-1 · Cited by 23 · see citing works

Target deconvolution with matrix-augmented pooling strategy reveals cell-specific drug-protein interactions

Ji, H., Lu, X. M., Zhao, S., Wang, Q., Liao, B. Y., Bauer, L. G., Huber, K., Luo, R., Tian, R., & Tan, C. S. H. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.08.002 · Cited by 21 · see citing works

Artificial intelligence in tumor drug resistance: Mechanisms and treatment prospects

Gu, J., Zhang, J., Zeng, S., Zhang, W., Xia, R., Wang, X., Zhou, Q., Guo, S., Wang, H., & Chen, Z.-S. (2025) · Intelligent Oncology · doi:10.1016/j.intonc.2025.02.001 · Cited by 20 · see citing works

Artificial intelligence and anti-cancer drugs' response

Long, X., Sun, K., Lai, S., Liu, Y., Su, J., Chen, W., Liu, R., He, X., Zhao, S., & Huang, K. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.05.009 · Cited by 20 · see citing works

Mutation profiles in circulating cell‐free DNA predict acquired resistance to olaparib in high‐grade serous ovarian carcinoma

Hu, D., Guo, E., Yang, B., Qin, X., Fu, Y., Fan, J., Zhuang, X., Yao, Q., Lu, F., Li, W., et al. (2022) · Cancer Science · doi:10.1111/cas.15456 · Cited by 20 · see citing works

Protomer selectivity of type II RAF inhibitors within the RAS/RAF complex

Vasta, J. D., Michaud, A., Zimprich, C., Beck, M., Swiatnicki, M., Zegzouti, H., Thomas, M. R., Wilkinson, J., Crapster, J. A., & Robers, M. B. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.07.019 · Cited by 16 · see citing works

Overloading And unpacKing (OAK) - droplet-based combinatorial indexing for ultra-high throughput single-cell multiomic profiling

Wu, B. C., Bennett, H. M., Ye, X., Sridhar, A., Eidenschenk, C., Everett, C., Nazarova, E. V., Chen, H.-H., Kim, I. K., DeAngelis, M. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53227-z · Cited by 18 · see citing works

Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer

Diehl, J. N., Hibshman, P. S., Ozkan‐Dagliyan, I., Goodwin, C. M., Howard, S. V., Cox, A. D., & Der, C. J. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.008 · Cited by 18 · see citing works

Hierarchical Virtual Screening Based on Rocaglamide Derivatives to Discover New Potential Anti-Skin Cancer Agents

dos Santos, I. V. F., Borges, R. S., Silva, G. M., de Lima, L. R., Bastos, R. S., Ramos, R. D. S., Silva, L. B., da Silva, C. H. T. D. P., & Santos, C. B. R. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.836572 · Cited by 18 · see citing works

Targeting RAF dimers in RAS mutant tumors: From biology to clinic

Yin, H., Tang, Q., Xia, H., & Bi, F. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.02.018 · Cited by 18 · see citing works

ARAF suppresses ERBB3 expression and metastasis in a subset of lung cancers

Mooz, J., Riegel, K., Hari, P. S., Sadanandam, A., Marini, F., Klein, M., Werner, U., Roth, W., Wilken‐Schmitz, A., Tegeder, I., et al. (2022) · Science Advances · doi:10.1126/sciadv.abk1538 · Cited by 17 · see citing works

Metabolic rewiring directs melanoma immunology

Sun, N., Tian, Y., Chen, Y., Guo, W., & Li, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.909580 · Cited by 17 · see citing works

Analysis of RAS and drug induced homo- and heterodimerization of RAF and KSR1 proteins in living cells using split Nanoluc luciferase

Rohrer, L., Spohr, C., Beha, C., Griffin, R., Braun, S. L., Halbach, S., & Brummer, T. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01146-9 · Cited by 17 · see citing works

Unique Spectrum of Activating BRAF Alterations in Prostate Cancer

Chehrazi‐Raffle, A., Tukachinsky, H., Toye, E., Sivakumar, S., Schrock, A. B., Bergom, H. E., Ebrahimi, H., Pal, S. K., Dorff, T. B., Agarwal, N., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1393 · Cited by 17 · see citing works

BRAF Δβ3-αC in-frame deletion mutants differ in their dimerization propensity, HSP90 dependence, and druggability

Lauinger, M., Christen, D., Klar, R. F. U., Roubaty, C., Heilig, C. E., Stumpe, M., Knox, J. J., Radulovich, N., Tamblyn, L., Xie, I. Y., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade7486 · Cited by 17 · see citing works

Plasma membrane-associated ARAF condensates fuel RAS-related cancer drug resistance

Li, W., Shi, X., Tan, C., Jiang, Z., Li, M., Ji, Z., Zhou, J., Luo, M., Fan, Z., Ding, Z., et al. (2025) · Nature Chemical Biology · doi:10.1038/s41589-024-01826-8 · Cited by 17 · see citing works

BRAFV600E;K601Q metastatic melanoma patient-derived organoids and docking analysis to predict the response to targeted therapy

Porcelli, L., Fonte, R., Pierri, C. L., Fucci, L., Saponaro, C., Armenio, A., Serratì, S., Strippoli, S., Fasano, R., Volpicella, M., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106323 · Cited by 16 · see citing works

Targeting Lung Cancer With Carvacrol‐Triazole‐Arylidene Hydrazide Hybrids: In Vitro and In Silico Cytotoxicity Assessments

Çakır, F., Ateşoğlu, Ş., Müderrisoğlu, Z. R., Demirel, F., Akbaş, F., Tokalı, F. S., & Şenol, H. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202402963 · Cited by 16 · see citing works

MITF activity is regulated by a direct interaction with RAF proteins in melanoma cells

Estrada, C., Mirabal-Ortega, L., Mery, L., Dingli, F., Besse, L., Messaoudi, C., Loew, D., Pouponnot, C., Bertolotto, C., Eychène, A., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03049-w · Cited by 15 · see citing works

Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial

Konopleva, M. Y., Dail, M., Daver, N. G., Garcia, J. S., Jonas, B. A., Yee, K. W. L., Kelly, K. R., Vey, N., Assouline, S. E., Roboz, G. J., et al. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.01.007 · Cited by 14 · see citing works

Novel RAF ‐directed approaches to overcome current clinical limits and block the RAS / RAF node

Scardaci, R., Berlinska, E., Scaparone, P., Michelina, S. V., Garbo, E., Novello, S., Santamarı́a, D., & Ambrogio, C. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13605 · Cited by 14 · see citing works

An overview of RAF kinases and their inhibitors (2019–2023)

Hashem, O., Shahin, A. I., Hindawi, M. A. A., Fageeri, M. F., Al-Sbbagh, S. A., Tarazi, H., & El-Gamal, M. I. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116631 · Cited by 14 · see citing works

Targeting the MAPK pathway for NRAS mutant melanoma: from mechanism to clinic

Wang, Y., Xu, G., & Xia, H. (2025) · British Journal of Dermatology · doi:10.1093/bjd/ljaf178 · Cited by 14 · see citing works

Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)

Hajjo, R., Sabbah, D. A., Bardaweel, S. K., & Zhong, H. A. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2327307 · Cited by 12 · see citing works

Unraveling lipid metabolism reprogramming for overcoming drug resistance in melanoma

Wang, R., Qin, Y., Liu, X., & Wu, J. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116122 · Cited by 13 · see citing works

Head-to-Head Comparison of BRAF/MEK Inhibitor Combinations Proposes Superiority of Encorafenib Plus Trametinib in Melanoma

Schulz, A., Raetz, J., Karitzky, P. C., Dinter, L., Tietze, J. K., Kolbe, I., Käubler, T., Renner, B., Beissert, S., Meier, F. E., et al. (2022) · Cancers · doi:10.3390/cancers14194930 · Cited by 13 · see citing works

Toxoplasma gondii infection regulates apoptosis of host cells via miR-185/ARAF axis

Su, D., Zhu, S., Hou, Z., Hao, F., Xu, K., Xu, F., Zhu, Y., Liu, D., Xu, J., & Tao, J. (2023) · Parasites & Vectors · doi:10.1186/s13071-023-05991-y · Cited by 13 · see citing works

CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP -Deleted Cancer

Knoll, N., Masser, S., Bordas, B., Ebright, R. Y., Li, G., Kesar, D., Destefanis, E., Kania, N., Rodriguez, D. J., Jen, J., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-1464 · Cited by 14 · see citing works

Melanoma with genetic alterations beyond the BRAF V600 mutation: management and new insights

Awada, G., & Neyns, B. (2022) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000817 · Cited by 12 · see citing works

RAS and SHOC2 Roles in RAF Activation and Therapeutic Considerations

Bonsor, D. A., & Simanshu, D. K. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-062822-030450 · Cited by 13 · see citing works

Combination of bulk RNA sequencing and scRNA sequencing uncover the molecular characteristics of MAPK signaling in kidney renal clear cell carcinoma

Li, X., Guan, H., Ma, C., Dai, Y., Su, J., Chen, X., Yuan, Q., & Wang, J. (2024) · Aging · doi:10.18632/aging.205436 · Cited by 12 · see citing works

Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma

Haugh, A. M., & DAUD, A. I. (2024) · American Journal of Clinical Dermatology · doi:10.1007/s40257-023-00841-0 · Cited by 12 · see citing works

Mechanisms of resistance to active state selective tri-complex RAS inhibitorsPreprint

Sang, B., Ye, L. F., Hu, F., Pourfarjam, Y., Cuevas-Navarro, A., Fan, S., Fu, Z. Q., Washington, A., Rodriguez, D. J., Vides, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.24.649345 · Cited by 12 · see citing works

Allosteric coupling asymmetry mediates paradoxical activation of BRAF by type II inhibitors

Rasmussen, D. M., Semonis, M. M., Greene, J. T., Muretta, J. M., Thompson, A. R., Ramos, S. T., Thomas, D. D., Pomerantz, W. C. K., Freedman, T. S., & Levinson, N. M. (2024) · eLife · doi:10.7554/elife.95481 · Cited by 11 · see citing works

Allosteric coupling asymmetry mediates paradoxical activation of BRAF by type II inhibitors

Rasmussen, D. M., Semonis, M. M., Greene, J. T., Muretta, J. M., Thompson, A. R., Ramos, S. T., Thomas, D. D., Pomerantz, W. C. K., Freedman, T. S., & Levinson, N. M. (2024) · eLife · doi:10.7554/elife.95481.2 · Cited by 11 · see citing works

Precision Oncology for Papillary Craniopharyngioma

Blakeley, J. O., & Shannon, K. (2023) · New England Journal of Medicine · doi:10.1056/nejme2305288 · Cited by 11 · see citing works

Exploring Molecular Genetic Alterations and RAF Fusions in Melanoma: A Belvarafenib Expanded Access Program in Patients with RAS/RAF -Mutant Melanoma

Kim, K. H., Cho, S. M., Jeong, Y., Baek, E. S., Lee, C., Ryu, H. J., Noh, Y. S., Hong, Y.-H., Chung, K. Y., Roh, M. R., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae018 · Cited by 10 · see citing works

Characterization and inhibitor sensitivity of ARAF, BRAF, and CRAF kinases

Tkacik, E., Jang, D. M., Boxer, K., Ha, B. H., & Eck, M. J. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110800 · Cited by 10 · see citing works

Implications of glutathione-S transferase P1 in MAPK signaling as a CRAF chaperone: In memory of Dr. Irving Listowsky

Niitsu, Y., Sato, Y., & Takayama, T. (2022) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.98.005 · Cited by 11 · see citing works

An Efficient Second-Generation Manufacturing Process for the pan-RAF Inhibitor Belvarafenib

Zell, D., Dalziel, M. E., Carrera, D. E., Stumpf, A. W., Bachmann, S., Mercado-Marin, E. V., Koenig, S. G., Zhang, H., & Gosselin, F. (2021) · Organic Process Research & Development · doi:10.1021/acs.oprd.1c00277 · Cited by 10 · see citing works

Mechanism of dimer selectivity and binding cooperativity of BRAF inhibitors

Clayton, J., Romany, A., Matenoglou, E., Gavathiotis, E., Poulikakos, P. I., & Shen, J. (2025) · eLife · doi:10.7554/elife.95334.4 · Cited by 9 · see citing works

NOVEL INSIGHTS IN ADVANCED THYROID CARCINOMA: FROM MECHANISMS TO TREATMENTS: Molecular insights into the origin, biology, and treatment of anaplastic thyroid carcinoma

Karimi, A. H., Zeng, P. Y., Cecchini, M. J., Barrett, J. W., Pan, H., Ying, S., Le, N., Mymryk, J. S., Ailles, L., & Nichols, A. C. (2025) · European Thyroid Journal · doi:10.1530/etj-25-0057 · Cited by 9 · see citing works

Melanoma: Pathogenesis and Targeted Therapy

Fu, Y., Liu, J., Mo, Z., Wang, B., Deng, Y., & Jiang, Y. (2026) · MedComm · doi:10.1002/mco2.70566 · Cited by 10 · see citing works

Individualized Treatment Strategy for Cutaneous Melanoma: Where Are We Now and Where Are We Going?

Zeng, H., Liu, F., Zhou, H., & Zeng, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.775100 · Cited by 9 · see citing works

Preclinical Activity of the Type II RAF Inhibitor Tovorafenib in Tumor Models Harboring Either a BRAF Fusion or an NF1 Loss-of-Function Mutation

Rastogi, S., Perino, S., Lal‐Nag, M., Wang, Y., Blackman, S. C., & Venetsanakos, E. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0451 · Cited by 8 · see citing works

Analysis of the ERK Pathway Cysteinome for Targeted Covalent Inhibition of RAF and MEK Kinases

Romany, A., Liu, R., Zhan, S., Clayton, J., & Shen, J. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00014 · Cited by 8 · see citing works

Combining single-cell and transcriptomic analysis revealed the immunomodulatory effect of GOT2 on a glutamine-dependent manner in cutaneous melanoma

Song, L., Wei, X., Zhang, X., & Lu, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1241454 · Cited by 8 · see citing works

Treatment outcome of NSCLC patients with BRAF mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in Germany

Kropf-Sanchen, C., Rasokat, A., Christopoulos, P., Wenzel, C., Wehler, T., Rost, M., Kulhavy, J., Reinmuth, N., Schulz, C. K. J., Scheffler, M., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105124 · Cited by 7 · see citing works

Dissecting the MAPK signaling landscape in malignant melanoma: from BRAF and NRAS mutations to precision combination therapies

Fang, X., Wang, S., & Fu, S. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1723066 · Cited by 7 · see citing works

Peptide inhibitors targeting Ras and Ras-associated protein–protein interactions

Han, D., Li, A., Zhu, L., Zhuang, C., Zhao, Q., & Zou, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116878 · Cited by 7 · see citing works

Current knowledge about immunotherapy resistance for melanoma and potential predictive and prognostic biomarkers

Song, L., Yang, Y., & Tian, X. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2023.150 · Cited by 5 · see citing works

Belvarafenib penetrates the BBB and shows potent antitumor activity in a murine melanoma brain metastasis model

Kim, Y.-Y., Park, H., Song, T., Choi, K., Dolton, M., Mao, J., Kim, J., Ahn, Y., Suh, K. H., & Kim, Y. H. (2023) · Clinical & Experimental Metastasis · doi:10.1007/s10585-023-10198-7 · Cited by 6 · see citing works

Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer

Zeng, P. Y., Meens, J., Karimi, A. H., Pan, H., Cecchini, M. J., Jarycki, L., Ryan, S. E. B., Dawson, A. E., Shaikh, M. H., Palma, D. A., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102820 · Cited by 5 · see citing works

Property-Based Prediction Uncovers Intestinal Excretion as an Elimination Route of Small-Molecule Drugs

Chen, C., Zhao, W., Cao, L., He, M., Khojasteh, S. C., Hop, C. E. C. A., Dragovich, P. S., Wright, M. R., & Zhang, D. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01251 · Cited by 5 · see citing works

The MEK–RAF molecular glue IK-595 has potent antitumor activity across RAS/MAPK pathway-altered cancers

Haines, E., Burke, M., Catterall, R., de Jesus, V., Hidalgo, D., Li, B., Manna, J., Yang, A., Cavanaugh, J., Wessel, S. R., et al. (2026) · Nature Cancer · doi:10.1038/s43018-025-01081-3 · Cited by 5 · see citing works

Allosteric coupling asymmetry mediates paradoxical activation of BRAF by type II inhibitorsPreprint

Rasmussen, D. M., Semonis, M. M., Greene, J. T., Muretta, J. M., Thompson, A. R., Ramos, S. T., Thomas, D. D., Pomerantz, W. C. K., Freedman, T. S., & Levinson, N. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.18.536450 · Cited by 5 · see citing works

Combination of the Novel RAF Dimer Inhibitor Brimarafenib With the MEK Inhibitor Mirdametinib Is Effective Against NRAS Mutant Melanoma

Tellenbach, F. L., Seiler, L., Johnson, M. P., Rehrauer, H., Schukla, P., Gómez, J. M. M., Stoffel, C. I., Kamal, A., Dummer, R., Levesque, M. P., et al. (2025) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.70062 · Cited by 4 · see citing works

Covalent pan-TEAD inhibitors block YAP activity and demonstrate brain penetrance in a Hippo-dependent cancer model

Hagenbeek, T. J., Zbieg, J. R., Smith, R., Paul, S., Gerosa, L., Torrini, C., Guarnaccia, A. D., Ong, C. C., Lacap, J. A., Ning, M., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-74722-5 · Cited by 4 · see citing works

Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors

Wang, J., Sarkar, A., García, N., Zhang, L., Calizo, A., Lisok, A., Campos, K., He, F., Punjaala, N., Marple, T. C., et al. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01353-9 · Cited by 4 · see citing works

Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated Melanoma

Niessner, H., Hüsch, A., Kosnopfel, C., Meinhardt, M., Westphal, D., Meier, F., Schilling, B., & Sinnberg, T. (2023) · Cancers · doi:10.3390/cancers15235521 · Cited by 3 · see citing works

Computational Modeling of Drug Response Identifies Mutant-Specific Constraints for Dosing panRAF and MEK Inhibitors in Melanoma

Goetz, A., Shanahan, F., Brooks, L., Lin, E., Mroue, R. M., Cruz, D. D., Hunsaker, T., Czech, B., Dixit, P. D., Segal, U., et al. (2024) · Cancers · doi:10.3390/cancers16162914 · Cited by 3 · see citing works

Rat Sarcoma Virus Family Genes in Acute Myeloid Leukemia: Pathogenetic and Clinical Implications

Khattab, S., Berisha, A., Baran, N., & Piccaluga, P. P. (2025) · Biomedicines · doi:10.3390/biomedicines13010202 · Cited by 3 · see citing works

Targeted therapy for pediatric glioma: RAF(t)ing in the molecular era

Shen, Z.-P., Zhang, Z., Li, N., Xu, L., & Chen, Y. (2025) · World Journal of Pediatrics · doi:10.1007/s12519-025-00889-4 · Cited by 3 · see citing works

Understanding cancer drug resistance with Sleeping Beauty functional genomic screens: Application to MAPK inhibition in cutaneous melanoma

Zhu, E. Y., Schillo, J. L., Murray, S., Riordan, J. D., & Dupuy, A. J. (2023) · iScience · doi:10.1016/j.isci.2023.107805 · Cited by 3 · see citing works

Characterizing the Molecular Mechanism of the Lethal C423D Mutation in FgMyoI: A Molecular Perspective

Bao, Y., Jia, F., Li, M., Xu, R., Xie, Y., Zhang, F., & Guo, J. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.3c08648 · Cited by 3 · see citing works

Targeting Hyperactive Ras Signaling in Pediatric CancerPreprint

Levinson, A. L., Shannon, K., & Huang, B. J. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041572 · Cited by 3 · see citing works

In Vivo Efficacy of ABHD17 Inhibition Validates the Palmitoylation Cycle as a Therapeutic Target in NRAS -Mutant CancerPreprint

Decker, M., Huang, B. J., Ware, T. B., Boone, C. D., Tang, M., Ybarra, J., Sale, M. J., Francois, R. A., Ballapuram, A. C., Taran, K. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.20.644389 · Cited by 3 · see citing works

Unveiling Common Transcriptomic Features between Melanoma Brain Metastases and Neurodegenerative Diseases

Soler-Sáez, I., Karz, A., Hidalgo, M. R., Gómez-Cabañes, B., López‐Cerdán, A., Català-Senent, J. F., Prutisto-Chang, K., Eskow, N. M., Izar, B., Redmer, T., et al. (2024) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2024.09.005 · Cited by 3 · see citing works

Phase I Clinical Trial Evaluating Safety, Tolerability, and Early Activity of Exarafenib (KIN-2787), a Highly Selective Pan-RAF Inhibitor, in BRAF -Altered Solid Tumors or NRAS -Mutant Melanoma

Gambardella, V., McKean, M. A., Kim, R., Kato, S., Cassier, P. A., Mehnert, J. M., Chmielowski, B., Gaudy‐Marqueste, C., Chen, C. T., Planchard, D., et al. (2026) · JCO oncology advances. · doi:10.1200/oa-25-00114 · Cited by 2 · see citing works

Dual inhibition of BRAF for cancer treatment: advances and therapeutic potential

Ren, C., Zhang, M., Liu, J., Zhang, L., Guan, X., Pu, S., & Li, J. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2575748 · Cited by 2 · see citing works

Inhibiting the Extracellular Signal-regulated Kinase 1/2 (ERK1/2) Cascade in Cancer and the Heart: for Better or Worse, in Sickness and Health?

Clerk, A., Amadi, S. U., Smith, S. J., & Sugden, P. H. (2024) · International Journal of Drug Discovery and Pharmacology · doi:10.53941/ijddp.2024.100006 · Cited by 2 · see citing works

Abstract 36: ARAF mutations confer resistance to RAF dimer inhibitors in NRAS and BRAF mutant melanoma

Malek, S. (2021) · Cancer Research · doi:10.1158/1538-7445.am2021-36

ARAF Mutations Limit Response to RAF Dimer Inhibition

(2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2021-069 · Cited by 4 · see citing works

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454 · see citing works

Abstract A012: Emergence of MEK1 mutations in RAF or RAS-mutant solid tumors following treatment with a combination of selective type II RAF inhibitor belvarafenib and MEK inhibitor cobimetinib

Hilz, S., Chen, M., Nowicka, M., Chakravarthy, H., Moshref, M., Gerosa, L., Eng‐Wong, J., Chou, C. K., Noh, Y. S., Hong, Y.-H., et al. (2024) · Cancer Research · doi:10.1158/1538-7445.canevol23-a012

Abstract IA7: Novel mechanisms of resistance in BRAF-mutant melanoma

Poulikakos, P. I. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.mechres-ia7